FOXP3 and type 1 diabetes mellitus: In addition to lowering quantities of pro-inflammatory cytokines and enhancing regulatory cytokines such as TGF- β, these constructs have been demonstrated to induce systemic immune tolerance and to protect from multiple autoimmune disorders including Type 1 Diabetes (T1D), Experimental Autoimmune Encephalomyelitis (EAE), and uveitis, through the induction of both Foxp3+ and Foxp3- Treg cells in murine models [16–20].